In this podcast episode recorded at the Thirteenth Annual Meeting of the Society of Hematologic Oncology (SOHO 2025), Megan Melody, MD, from Tampa General Hospital, spoke with Tycel J. Phillips, MD, from the City of Hope Cancer Center, on the latest advancements in mantle cell lymphoma (MCL), including the phase 1/2 trial in relapsed or refractory MCL recently published in the Journal of Clinical Oncology.
In the trial led by Dr. Phillips, the investigators evaluated glofitamab monotherapy in patients with relapsed or refractory B-cell lymphomas, with obinutuzumab pretreatment to mitigate the risk of cytokine release syndrome with glofitamab.
Dr. Phillips also spoke about treating patients with relapsed or refractory non-Hodgkin lymphoma with venetoclax.
